Key result
Modular rewiring of the MYBPC3 promoter boosts expression to rescue haploinsufficiency across variants.
Why the study?
Therapeutic gene editing for numerous unique MYBPC3 loss-of-function variants in HCM faces regulatory and logistical challenges, and the capacity to modulate native MYBPC3 transcription is unknown.
Rational mapping and redesign of the MYBPC3 promoter can robustly upregulate expression in human cardiomyocytes, providing a scalable blueprint for gene therapies treating haploinsufficient hypertrophic cardiomyopathy.
May support promoter editing for MYBPC3-HCM; leaves open translation from iPSC models to clinical use.
Autosomal dominant loss-of-function variants in the gene MYBPC3 are, collectively, the most common genetic cause of hypertrophic cardiomyopathy (HCM) and are a prototype of haploinsufficient human disease. Typical for haploinsufficiency-associated genes, hundreds of unique loss-of-function pathogenic variants have been reported for MYBPC3 – therapeutic gene editing to correct each of these variants poses major regulatory and logistical hurdles. Upregulating wild-type allele expression could offer a generalizable therapeutic strategy, but the capacity to modulate native MYBPC3 transcription is unknown. Here, we present a variant-agnostic approach to rescue haploinsufficiency by mapping and rationally redesigning the MYBPC3 promoter. Using massively parallel reporter assays (MPRAs) in human induced pluripotent stem cell-derived cardiomyocytes, we performed saturation mutagenesis of the MYBPC3 promoter at single base-pair resolution. This defined a new class of clinically relevant noncoding loss-of-function variants while revealing essential cis-regulatory grammar anchored by key transcription factor binding sites (TFBSs). Furthermore, by systematically screening thousands of variant combinations, modular promoter elements, and heterologous TFBS insertions, we identified synergistic sequence edits that drive robust increases in MYBPC3 expression. Together, our findings improve the clinical interpretation of noncoding variants and establish a scalable blueprint for promoter editing to treat MYBPC3 -associated HCM and other haploinsufficient diseases.
No takes yet. Share an insight, caveat, or question.
Renberg et al. (2026) studied Hypertrophic cardiomyopathy. Saturation mutagenesis and rational redesign of the MYBPC3 promoter vs. Wild-type MYBPC3 promoter was evaluated on Transcriptional activity measured by massively parallel reporter assays (MPRAs). Systematic mutagenesis and modular rewiring of the MYBPC3 promoter drove robust increases in MYBPC3 expression, offering a variant-agnostic strategy to rescue haploinsufficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: